


# Accepted Manuscript



Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania

Jacob R. Stephens , Jaimee L. Heffner , PhD Caleb M. Adler , MD Thomas J. Blom , MS Robert M. Anthenelli , MD David E. Fleck , PhD Jeffrey A. Welge , PhD Stephen M. Strakowski , MD Melissa P. DelBello , MD

PII: S0890-8567(14)00302-5

DOI: [10.1016/j.jaac.2014.04.018](https://doi.org/10.1016/j.jaac.2014.04.018)

Reference: JAAC 1007

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*

Received Date: 15 August 2013

Revised Date: 31 March 2014

Accepted Date: 6 April 2014

Please cite this article as: Stephens JR, Heffner JL, Adler CM, Blom TJ, Anthenelli RM, Fleck DE, Welge JA, Strakowski SM, DelBello MP, Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania, *Journal of the American Academy of Child & Adolescent Psychiatry* (2014), doi: 10.1016/j.jaac.2014.04.018.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania

RH = Risk Factors for SUD in Bipolar Adolescents

Jacob R. Stephens; Jaimee L. Heffner, PhD; Caleb M. Adler, MD; Thomas J. Blom, MS; Robert M. Anthenelli, MD; David E. Fleck, PhD; Jeffrey A. Welge, PhD; Stephen M. Strakowski, MD; Melissa P. DelBello, MD

Clinical guidance is available at the end of this article.

Accepted May 1, 2014

This article was reviewed under and accepted by deputy editor Ellen Leibenluft, MD

Mr. Stephens is with the Research, Observation, Service, Education (ROSE) Program and the Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH. Dr. Heffner is with the Fred Hutchinson Cancer Research Center, Seattle, WA, and the Division of Bipolar Disorders Research, University of Cincinnati College of Medicine. Drs. Adler, Fleck, Welge, Strakowski, DelBello, and Mr. Blom are with the Division of Bipolar Disorders Research, University of Cincinnati College of Medicine. Dr. Anthenelli is with the University of California at San Diego, San Diego, CA and the VA San Diego Healthcare System, San Diego, CA.

Funding for this study came from National Institute of Mental Health (NIMH) grants #63373 (MPD) and #58170 (SMS) and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant 8 UL1 TR000077-05. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or NIH.

Dr. Welge served as the statistical expert for this research.

Disclosure: Dr. Heffner has served as a consultant for Pfizer. Dr. Adler has received research support from AstraZeneca, Amylin, Eli Lilly and Co., GlaxoSmithKline, Lundbeck, Martek, Merck, Novartis, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda. He has been on the lecture bureau for Merck and Sunovion, for which he has received honoraria. Dr. Anthenelli has received research support from Pfizer, GlaxoSmithKline, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the Department of Veterans Affairs. He also provides consultancy and/or advisory board services to Pfizer. Dr. Fleck has received research support from NIH and honoraria from Elsevier and the US Army Medical Research and Materiel Command (USAMRMC). Dr. Strakowski serves as Chair of Data and Safety Monitoring Boards (DSMBs) for Sunovion Pharmaceutical and Novartis and as a consultant to Procter and Gamble. Dr. DelBello has received grant or research support from NIMH, NIAAA, NIDA, the National Institute of Diabetes and Digestive and Kidney Diseases, the Depressive and Bipolar Alternative Treatment Foundation, the University of Cincinnati Neuroscience Institute, AstraZeneca, Amylin, Eli Lilly and Co., Pfizer, Otsuka, GlaxoSmithKline, Merck, Martek, Novartis, Lundbeck, Purdue, Sunovion, and Shire. She has

Download English Version:

<https://daneshyari.com/en/article/6797109>

Download Persian Version:

<https://daneshyari.com/article/6797109>

[Daneshyari.com](https://daneshyari.com)